Aricept
4.1 (5 customer reviews)Adults diagnosed with Alzheimer’s dementia may be prescribed Aricept to support memory, attention, and day-to-day functioning. Aricept contains donepezil, an acetylcholinesterase inhibitor that increases the availability of acetylcholine, a chemical messenger involved in cognition.
Product information
Aricept contains donepezil, an acetylcholinesterase inhibitor that increases the availability of acetylcholine, a chemical messenger involved in cognition. Donepezil belongs to the acetylcholinesterase inhibitor class and is used for symptomatic treatment of Alzheimer’s dementia, including mild, moderate, and severe stages.
Ingredients
Aricept tablets contain donepezil hydrochloride. Donepezil belongs to the acetylcholinesterase inhibitor class and is used for symptomatic treatment of Alzheimer’s dementia, including mild, moderate, and severe stages.
Acetylcholine helps nerve cells communicate. In Alzheimer’s disease, acetylcholine activity decreases as nerve cells are damaged. Donepezil slows the breakdown of the acetylcholine that remains, which may help preserve cognitive function and daily abilities for a period of time. The FDA-approved prescribing information identifies nausea, diarrhoea, insomnia, muscle cramps, fatigue, and reduced appetite among the commonly reported effects of donepezil. [1]
Aricept does not reverse Alzheimer’s disease or restore lost nerve cells. Its role is to help maintain cognitive and functional abilities in people who respond to treatment.
Therapeutic indications
Adults diagnosed with Alzheimer’s dementia may be prescribed Aricept to support memory, attention, and day-to-day functioning.
Donepezil belongs to the acetylcholinesterase inhibitor class and is used for symptomatic treatment of Alzheimer’s dementia, including mild, moderate, and severe stages.
Dosage and administration
Aricept tablets are usually taken once daily, at the prescribed dose and at a consistent time. The regimen for the chosen strength is confirmed with a healthcare professional before starting. Evening use is common, though morning administration may suit people who develop vivid dreams or disturbed sleep.
- Swallow the tablet with water.
- Take it at the same time each day.
- It may be taken with or without food.
- Continue regular use unless the prescriber advises otherwise.
- If a dose is missed, take the next scheduled dose at the usual time.
- Do not take two doses together to compensate for a missed tablet.
- If treatment has been interrupted for several days, contact the prescriber before restarting because the dose may need reassessment.
A common mistake is judging Aricept after only a few days. Donepezil changes acetylcholine signalling, not alertness in the way a stimulant does. Cognitive benefit is assessed across weeks and months, ideally with observations from the person and a regular caregiver.
When not to use it
- A slow pulse, sick sinus syndrome, heart block, recurrent fainting, or an implanted cardiac device.
- Active stomach or duodenal ulcer disease, or regular use of medicines that raise gastrointestinal bleeding risk.
- Asthma or chronic obstructive pulmonary disease, because cholinergic activity can narrow the airways.
- A history of seizures.
- Difficulty passing urine or bladder outflow obstruction.
- Significant liver impairment, where dose selection may require closer clinical review.
- Pregnancy or breastfeeding, where specialist assessment is needed.
Medicines that can slow the heart rate, including some beta-blockers and rhythm medicines, may add to donepezil’s cardiac effect. Anticholinergic medicines can oppose its action, while strong CYP3A4 inhibitors or inducers may alter donepezil exposure. Anaesthetists also need to know about donepezil before an operation because it can affect responses to certain muscle relaxants.
When this is not for you
This medication is not for you if you have had a serious allergic reaction to donepezil, piperidine derivatives, or a tablet ingredient.
Possible side effects
Digestive effects are the most frequent reason people find Aricept difficult at first. Nausea, diarrhoea, vomiting, reduced appetite, and abdominal discomfort may occur, especially when treatment begins or the dose changes.
Sleep can also be affected. Some people report insomnia, vivid dreams, or nightmares. Others feel tired or dizzy. Muscle cramps, headache, and increased urinary frequency can occur.
The most useful practical responses are simple:
- Take the tablet after food if nausea occurs.
- Consider morning dosing if dreams become disruptive.
- Ensure regular fluids if diarrhoea develops.
- Rise slowly from bed or a chair if dizziness occurs.
- Record fainting, severe vomiting, black stools, or marked appetite loss promptly.
Donepezil can slow heart rate and may increase the risk of fainting in susceptible people. A person with an unexplained collapse, a new irregular heartbeat, chest discomfort, or repeated dizziness needs timely medical assessment.
Aricept may help cognition, yet it can also create an early tolerability hurdle. A slow and supervised treatment approach gives the best chance of seeing whether benefits outweigh unwanted effects.
How it affects the body
Donepezil blocks acetylcholinesterase, the enzyme that normally breaks down acetylcholine in the brain. More acetylcholine remains available between nerve cells, supporting communication in areas involved in memory, orientation, language, and practical tasks.
The effect is gradual. Family members may notice small changes first: fewer repeated questions, better participation in familiar routines, or less difficulty following a conversation. These improvements are not identical for every person, and some people experience little noticeable change.
A Cochrane review found that donepezil can produce modest benefits in cognition and daily functioning for people with Alzheimer’s dementia, balanced against a higher likelihood of gastrointestinal adverse effects. [2]
Common mistakes
- Stopping after a few unsettled nights: Sleep disruption may improve after changing the administration time rather than ending treatment immediately.
- Doubling a missed dose: This increases the chance of nausea, vomiting, dizziness, and a slow pulse.
- Assuming worsening memory proves treatment failure: Dementia can progress despite treatment. The meaningful question is whether function is better maintained than it might otherwise be.
- Ignoring weight loss: Appetite changes deserve attention, especially in frail older adults with low body weight.
- Starting new medicines without reviewing the full regimen: Bladder medicines, sedating antihistamines, and some nausea treatments can affect cognition or interact pharmacologically.
- Relying only on memory to assess results: A brief weekly note from a caregiver often gives a clearer picture than an isolated impression.
Comparison
Aricept is one of several medicines used to manage Alzheimer’s dementia symptoms. Choice depends on disease stage, prior response, tolerability, swallowing ability, cardiac history, and the treatment plan.
| Active ingredient or approach | Main mechanism | Typical clinical role |
|---|---|---|
| Donepezil in Aricept | Acetylcholinesterase inhibition | Cognitive symptom treatment across Alzheimer’s dementia stages |
| Rivastigmine | Acetylcholinesterase and butyrylcholinesterase inhibition | Alternative when donepezil is poorly tolerated or another formulation is preferred |
| Memantine | NMDA receptor modulation | Often used in moderate-to-severe Alzheimer’s dementia, alone or alongside an acetylcholinesterase inhibitor |
Donepezil, rivastigmine, and galantamine work through cholinergic pathways. They can cause similar digestive effects and may slow the heart rate. Memantine works differently by reducing excessive glutamate signalling at NMDA receptors, so its adverse-effect pattern differs.
NICE guidance supports acetylcholinesterase inhibitors for Alzheimer’s disease and describes memantine as an option in defined stages or circumstances. [3]
What doctors say
In clinical practice, doctors usually set realistic goals for Aricept. They look for slower functional decline, steadier attention, or retained independence in familiar tasks rather than a cure for dementia.
Treatment success is often easier for a spouse, adult child, or regular carer to identify than for the person taking the tablet. A clinician may ask whether the person still recognises routine places, follows one-step instructions, joins meals, or manages personal care with the same level of prompting.
WHO dementia guidance stresses person-centred care, caregiver support, and regular review of function alongside drug treatment. [4] Aricept works best as one part of a plan that also addresses sleep, hearing, vision, hydration, mobility, routine, and safety at home.
Comparison
Common questions
How long does one Aricept dose keep working?
Donepezil remains active in the body for a long time, which is why Aricept is generally used once daily rather than several times a day. Its long elimination half-life supports stable acetylcholinesterase inhibition between doses. The clinical effect is not judged by how a person feels after one tablet; it builds with regular treatment. The FDA prescribing information from 2021 describes the pharmacokinetic profile and daily administration approach for donepezil. [5]
Driving, concentration and machinery use
Alzheimer’s dementia itself can impair attention, judgement, reaction time, and orientation, so driving and machinery decisions must reflect the person’s functional ability. Aricept may also cause dizziness, fatigue, fainting, or sleep disturbance, especially early in treatment. MOHAP-aligned clinical practice in 2026 requires individual assessment where cognitive impairment affects road safety or workplace risk. A person who feels dizzy, unusually sleepy, confused, or faint should not drive or operate machinery.
Use in older adults
Aricept is commonly prescribed to older adults because Alzheimer’s dementia is more frequent with increasing age. Older people can be more sensitive to dehydration, weight loss, slow heart rate, and falls, making early monitoring useful. The WHO's 2019 guidance identifies dementia as a major health concern in ageing populations and supports regular review of cognition, daily function, and caregiver needs. Age alone does not prevent treatment, though frailty and other medicines may shape the plan.
Stopping treatment and tapering
Aricept should not be stopped abruptly without discussing the reason with the prescriber. Donepezil does not cause dependence in the way sedatives or opioid medicines can, yet cognitive or behavioural decline may become more apparent after withdrawal. NICE guidance from 2018 supports periodic review of benefit, adverse effects, goals of care, and changes in health status when deciding whether to continue treatment. A clinician may advise a monitored reduction or a direct stop depending on the individual situation.
Differences between Aricept and rivastigmine
Aricept contains donepezil, while rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase. Both treatments aim to support cholinergic signalling in Alzheimer’s dementia, though they differ in metabolism, formulations, and individual tolerability. The MHRA's 2019 product information describes acetylcholinesterase inhibitors as medicines that require consideration of gastrointestinal effects, heart-rate effects, and interactions with other treatments. A switch may be considered when one option causes persistent adverse effects or does not fit the person’s treatment routine.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Sources
- U.S. Food and Drug Administration (2021). Aricept (donepezil hydrochloride) prescribing information.
- Cochrane (2018). Donepezil for dementia due to Alzheimer’s disease.
- National Institute for Health and Care Excellence (2018). Dementia: assessment, management and support for people living with dementia and their carers.
- World Health Organization (2019). Risk reduction of cognitive decline and dementia: WHO guidelines.
- Medicines and Healthcare products Regulatory Agency (2019). Aricept 5 mg film-coated tablets: Summary of Product Characteristics.